173 related articles for article (PubMed ID: 25596377)
1. Is vaccine type seropositivity a marker for human papillomavirus vaccination? National Health and Nutrition Examination Survey, 2003-2010.
Petrosky EY; Hariri S; Markowitz LE; Panicker G; Unger ER; Dunne EF
Int J Infect Dis; 2015 Apr; 33():137-41. PubMed ID: 25596377
[TBL] [Abstract][Full Text] [Related]
2. Prevaccine era human papillomavirus types 6, 11, 16 and 18 seropositivity in the U.S.A., National Health and Nutrition Examination Surveys, 2003-2006.
Introcaso CE; Dunne EF; Hariri S; Panicker G; Unger ER; Markowitz LE
Sex Transm Infect; 2014 Sep; 90(6):505-8. PubMed ID: 24748563
[TBL] [Abstract][Full Text] [Related]
3. Mucosal and cutaneous Human Papillomavirus seroprevalence among adults in the prevaccine era in Germany - Results from a nationwide population-based survey.
Loenenbach AD; Poethko-Müller C; Pawlita M; Thamm M; Harder T; Waterboer T; Schröter J; Deleré Y; Wichmann O; Wiese-Posselt M
Int J Infect Dis; 2019 Jun; 83():3-11. PubMed ID: 30904676
[TBL] [Abstract][Full Text] [Related]
4. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010.
Markowitz LE; Hariri S; Lin C; Dunne EF; Steinau M; McQuillan G; Unger ER
J Infect Dis; 2013 Aug; 208(3):385-93. PubMed ID: 23785124
[TBL] [Abstract][Full Text] [Related]
5. Declines in Prevalence of Human Papillomavirus Vaccine-Type Infection Among Females after Introduction of Vaccine - United States, 2003-2018.
Rosenblum HG; Lewis RM; Gargano JW; Querec TD; Unger ER; Markowitz LE
MMWR Morb Mortal Wkly Rep; 2021 Mar; 70(12):415-420. PubMed ID: 33764964
[TBL] [Abstract][Full Text] [Related]
6. Human Papillomavirus neutralizing and cross-reactive antibodies induced in HIV-positive subjects after vaccination with quadrivalent and bivalent HPV vaccines.
Faust H; Toft L; Sehr P; Müller M; Bonde J; Forslund O; Østergaard L; Tolstrup M; Dillner J
Vaccine; 2016 Mar; 34(13):1559-1565. PubMed ID: 26896686
[TBL] [Abstract][Full Text] [Related]
7. HPV Serology Testing Confirms High HPV Immunisation Coverage in England.
Mesher D; Stanford E; White J; Findlow J; Warrington R; Das S; Pebody R; Borrow R; Soldan K
PLoS One; 2016; 11(3):e0150107. PubMed ID: 26959232
[TBL] [Abstract][Full Text] [Related]
8. Impact of human papillomavirus vaccination on racial/ethnic disparities in vaccine-type human papillomavirus prevalence among 14-26 year old females in the U.S.
Hirth J; McGrath CJ; Kuo YF; Rupp RE; Starkey JM; Berenson AB
Vaccine; 2018 Nov; 36(50):7682-7688. PubMed ID: 30377066
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of Human Papillomavirus Among Females After Vaccine Introduction-National Health and Nutrition Examination Survey, United States, 2003-2014.
Oliver SE; Unger ER; Lewis R; McDaniel D; Gargano JW; Steinau M; Markowitz LE
J Infect Dis; 2017 Sep; 216(5):594-603. PubMed ID: 28931217
[TBL] [Abstract][Full Text] [Related]
10. Long-term immunogenicity, effectiveness, and safety of nine-valent human papillomavirus vaccine in girls and boys 9 to 15 years of age: Interim analysis after 8 years of follow-up.
Olsson SE; Restrepo JA; Reina JC; Pitisuttithum P; Ulied A; Varman M; Van Damme P; Moreira ED; Ferris D; Block S; Bautista O; Gallagher N; McCauley J; Luxembourg A
Papillomavirus Res; 2020 Dec; 10():100203. PubMed ID: 32659510
[TBL] [Abstract][Full Text] [Related]
11. Two-dose schedules for human papillomavirus vaccine: Systematic review and meta-analysis.
D'Addario M; Redmond S; Scott P; Egli-Gany D; Riveros-Balta AX; Henao Restrepo AM; Low N
Vaccine; 2017 May; 35(22):2892-2901. PubMed ID: 28455170
[TBL] [Abstract][Full Text] [Related]
12. Sustainability of neutralising antibodies induced by bivalent or quadrivalent HPV vaccines and correlation with efficacy: a combined follow-up analysis of data from two randomised, double-blind, multicentre, phase 3 trials.
Mariz FC; Gray P; Bender N; Eriksson T; Kann H; Apter D; Paavonen J; Pajunen E; Prager KM; Sehr P; Surcel HM; Waterboer T; Müller M; Pawlita M; Lehtinen M
Lancet Infect Dis; 2021 Oct; 21(10):1458-1468. PubMed ID: 34081923
[TBL] [Abstract][Full Text] [Related]
13. Evaluation on the persistence of anti-HPV immune responses to the quadrivalent HPV vaccine in Chinese females and males: Up to 3.5 years of follow-up.
Huang T; Liu Y; Li Y; Liao Y; Shou Q; Zheng M; Liao X; Li R
Vaccine; 2018 Mar; 36(11):1368-1374. PubMed ID: 29428178
[TBL] [Abstract][Full Text] [Related]
14. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years.
Einstein MH; Baron M; Levin MJ; Chatterjee A; Fox B; Scholar S; Rosen J; Chakhtoura N; Meric D; Dessy FJ; Datta SK; Descamps D; Dubin G;
Hum Vaccin; 2011 Dec; 7(12):1343-58. PubMed ID: 22048173
[TBL] [Abstract][Full Text] [Related]
15. Declines in Vaccine-Type Human Papillomavirus Prevalence in Females Across Racial/Ethnic Groups: Data From a National Survey.
McClung NM; Lewis RM; Gargano JW; Querec T; Unger ER; Markowitz LE
J Adolesc Health; 2019 Dec; 65(6):715-722. PubMed ID: 31515134
[TBL] [Abstract][Full Text] [Related]
16. Use of quadrivalent human papillomavirus vaccine and the prevalence of antibodies to vaccine-targeted strains among female service members before and after vaccination.
Hurt L; Nsouli-Maktabi H; Rohrbeck P; Clark LL
MSMR; 2016 Feb; 23(2):6-13. PubMed ID: 26930146
[TBL] [Abstract][Full Text] [Related]
17. Long term follow up of persistence of immunity following quadrivalent Human Papillomavirus (HPV) vaccine in immunocompromised children.
MacIntyre CR; Shaw PJ; Mackie FE; Boros C; Marshall H; Seale H; Kennedy SE; Moa A; Chughtai AA; Trent M; O'Loughlin EV; Stormon M
Vaccine; 2019 Sep; 37(37):5630-5636. PubMed ID: 31402238
[TBL] [Abstract][Full Text] [Related]
18. Association between human papillomavirus vaccine status and sexually transmitted infection outcomes among females aged 18-35 with a history of sexual activity in the United States: A population survey-based cross-sectional analysis.
Closson K; Karim ME; Sadarangani M; Naus M; Ogilvie GS; Donken R
Vaccine; 2020 Dec; 38(52):8396-8404. PubMed ID: 33239227
[TBL] [Abstract][Full Text] [Related]
19. Antibody response to human papillomavirus vaccination and natural exposure in individuals with Fanconi Anemia.
Mehta PA; Sauter S; Zhang X; Davies SM; Wells SI; Myers KC; Panicker G; Unger ER; Butsch Kovacic M
Vaccine; 2017 Dec; 35(48 Pt B):6712-6719. PubMed ID: 29042204
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years.
Einstein MH; Baron M; Levin MJ; Chatterjee A; Fox B; Scholar S; Rosen J; Chakhtoura N; Lebacq M; van der Most R; Moris P; Giannini SL; Schuind A; Datta SK; Descamps D;
Hum Vaccin; 2011 Dec; 7(12):1359-73. PubMed ID: 22048172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
